Scleroderma secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
==Secondary Prevention==
==Secondary Prevention==
*There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of [[pulmonary arterial hypertension]] and scleroderma [[renal]] crisis in patients with scleroderma include:<ref name="pmid19389575">{{cite journal |vauthors=McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J |title=ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association |journal=J. Am. Coll. Cardiol. |volume=53 |issue=17 |pages=1573–619 |date=April 2009 |pmid=19389575 |doi=10.1016/j.jacc.2009.01.004 |url=}}</ref><ref name="pmid24022584">{{cite journal |vauthors=Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV |title=Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension |journal=Arthritis Rheum. |volume=65 |issue=12 |pages=3194–201 |date=December 2013 |pmid=24022584 |pmc=3883571 |doi=10.1002/art.38172 |url=}}</ref><ref name="pmid20534372">{{cite journal |vauthors=Khanna D, Denton CP |title=Evidence-based management of rapidly progressing systemic sclerosis |journal=Best Pract Res Clin Rheumatol |volume=24 |issue=3 |pages=387–400 |date=June 2010 |pmid=20534372 |pmc=2884006 |doi=10.1016/j.berh.2009.12.002 |url=}}</ref>
*There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of [[pulmonary arterial hypertension]] and scleroderma [[renal]] crisis in patients with scleroderma include:<ref name="pmid19389575">{{cite journal |vauthors=McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J |title=ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association |journal=J. Am. Coll. Cardiol. |volume=53 |issue=17 |pages=1573–619 |date=April 2009 |pmid=19389575 |doi=10.1016/j.jacc.2009.01.004 |url=}}</ref><ref name="pmid24022584">{{cite journal |vauthors=Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV |title=Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension |journal=Arthritis Rheum. |volume=65 |issue=12 |pages=3194–201 |date=December 2013 |pmid=24022584 |pmc=3883571 |doi=10.1002/art.38172 |url=}}</ref><ref name="pmid20534372">{{cite journal |vauthors=Khanna D, Denton CP |title=Evidence-based management of rapidly progressing systemic sclerosis |journal=Best Pract Res Clin Rheumatol |volume=24 |issue=3 |pages=387–400 |date=June 2010 |pmid=20534372 |pmc=2884006 |doi=10.1016/j.berh.2009.12.002 |url=}}</ref>
**Annual screening with trans thoracic echocardiogram ([[TTE]]) and [[Pulmonary function tests|pulmonary function tests (PFTs)]] for [[pulmonary hypertension]]
**Annual screening with trans thoracic echocardiogram ([[TTE]]) and [[Pulmonary function tests|pulmonary function tests (PFTs)]] for [[pulmonary hypertension]].
**Regular [[blood pressure]] monitoring at home for early detection of scleroderma renal crisis
**Regular [[blood pressure]] monitoring at home for early detection of scleroderma renal crisis.


==References==
==References==

Revision as of 19:56, 11 May 2018

Scleroderma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Scleroderma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Scleroderma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Scleroderma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Scleroderma secondary prevention

CDC on Scleroderma secondary prevention

Scleroderma secondary prevention in the news

Blogs on Scleroderma secondary prevention

Directions to Hospitals Treating Scleroderma

Risk calculators and risk factors for Scleroderma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of pulmonary arterial hypertension and scleroderma renal crisis in patients with scleroderma include screening.

Secondary Prevention

References

  1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association". J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.
  2. Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV (December 2013). "Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension". Arthritis Rheum. 65 (12): 3194–201. doi:10.1002/art.38172. PMC 3883571. PMID 24022584.
  3. Khanna D, Denton CP (June 2010). "Evidence-based management of rapidly progressing systemic sclerosis". Best Pract Res Clin Rheumatol. 24 (3): 387–400. doi:10.1016/j.berh.2009.12.002. PMC 2884006. PMID 20534372.

Template:WH Template:WS